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TO THE EDITOR
The paper by Eckman et al. (2008) offers
new insights into the behavior of circu-
lating basophils in chronic ‘‘idiopathic’’
urticaria. The authors detected autoanti-
bodies against the high-affinity immuno-
globulin E (IgE) receptor (FceRI) or IgE in
the majority of patients and healthy
controls by a sensitive immunoenzy-
matic assay. They showed that the levels
remained steady during follow-up and
did not fall significantly after disease
remission. They conclude that unknown
serological factors or primary basophil
abnormalities may be important in the
pathogenesis of the disease. They imply
this provides further evidence that anti-
FceRI and anti-IgE autoantibodies are not
pathogenic. However, there is a large
and increasing body of clinical and
laboratory evidence in favor of an
autoimmune subset of patients with
chronic urticaria who would previously
have been labeled idiopathic. The term
autoimmune urticaria has been in use for
almost a decade (Grattan and Francis,
1999). Functional autoantibodies that
release histamine from healthy donor
basophils have been demonstrated in at
least 30% of chronic ‘‘idiopathic’’ urti-
caria patients since 1991 (Grattan et al.,
1991). Unfortunately, the histamine re-
leasing activity of sera was not assessed
by Eckman et al., so it is not possible to
compare their results directly with those
of others who have reported functional
autoantibodies using basophil or mast
cell assays. The limitations of serum-
induced basophil histamine release are
well recognized but superiority of the
immunoenzymatic assay has not been
shown in parallel studies. Use of both
tests would clarify whether they define
the same population of chronic urticaria
patients or not.
Using the etiological term ‘‘idio-
pathic’’ implies that none of the pa-
tients had an autoimmune etiology and
this is at variance with current interna-
tional opinion. The alternative term
ordinary urticaria (Grattan and Hum-
phreys, 2007) makes no such assump-
tions about etiology as it describes a
clinical pattern of disease presenting
with continuous spontaneous weals,
with or without angioedema but
it does exclude physical urticarias,
angioedema without weals, urticarial
vasculitis, contact urticaria, and auto-
inflammatory syndromes presenting
with urticaria for which there is cur-
rently no evidence of an autoimmune
etiology.
The key to understanding the etiol-
ogy of urticaria is what stimulates
degranulation of cutaneous mast cells,
rather than circulating basophils, as
they are widely acknowledged to be
the primary effector cell in almost all
clinical patterns of urticaria. Local
events at the level of the mast cell
rather than in the blood may provide
answers. Histamine releasing activity of
chronic urticaria sera on mast cells
from newborn foreskin has been de-
monstrated (Niimi et al., 1996; Ferrer
and Kinet, 1998) The same sera re-
leased histamine from healthy donor
basophils. Studies of the delayed phase
response of IgE-mediated hypersensitiv-
ity reactions have shown that basophils
are important in the development of
chronic allergic inflammation in a
murine model (Mukai et al., 2005).
The presence of basophils has been
shown in cutaneous infiltrates in urti-
carial wheals (Ying et al., 2002) but
their role is less clear. It is therefore
unconvincing to ascribe a basophil
functional abnormality as ‘‘a primary
feature of the pathogenesis associated
with chronic urticaria’’.
Anti-IgE autoantibodies were de-
tected by immunoassay in chronic
urticaria, atopic dermatitis, and healthy
controls (Quinti et al., 1986) several
years before they were shown to have
in vitro functional properties in chronic
urticaria (Grattan et al., 1991) so it was
perhaps unsurprising that anti-FceRIa
autoantibodies have been found in
healthy controls (Horn et al., 1999)
and other autoimmune disorders
(Fiebiger et al., 1998). Current evidence
strongly suggests that the functionality
of these autoantibodies depends
on additional factors including co-
activation of mast cells by complement
(Ferrer and Nakazawa, 1999) and
the subclass of IgG (Soundararajan
et al., 2005). Neither of these were
examined by Eckman et al. A hypoth-
esis of conditional autoimmunity (Horn
et al., 2001) proposes that functionality
of anti-FceRIa autoantibodies depends
on skin mast cell receptor occupancy
by IgE under the control of local
environmental influences, with the im-
plication that degranulation depends
both on the soil (the cutaneous mast
cell) and the seed (the presence of
autoantibodies, with or without rele-
vant cofactors).
The local tissue concentration of
autoantibody rather than circulating
plasma concentrations may determine
whether sufficient receptors can be
cross-linked or not to initiate degranu-
lation.
The subjects in the study of Eckman
et al. with profound basopenia who
were labeled CIU-unclassified because
there were insufficient basophils to
assess anti-IgE responsiveness probably
correspond to the subgroup of chronic
urticaria patients with functional
histamine releasing autoantibodies and
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Abbreviation: IEMA, immunoenzymatic assay
absent circulating basophils identified
previously (Grattan et al., 1997). It is
therefore of interest that the mean level
of anti-FceRIa detected by immunoen-
zymatic assay was substantially and
significantly higher than other chronic
urticaria patients with enough circulat-
ing basophils to assess responsiveness
to anti-IgE. This would support the
possibility that the level of autoanti-
body may be a factor in determining
functionality. Testing chronic urticaria
basophil responsiveness to a monoclo-
nal anti-FceRIa in addition to anti-IgE
would seem appropriate in the
context of defining basophil phenotypes
in a disease that is believed to be caused
by both. Debate about the importance of
autoantibodies in urticaria pathogenesis
will no doubt continue but it is impor-
tant not to be side-lined from the
autoimmune hypothesis on the strength
of work that only shows part of a much
wider portfolio of clinical and laboratory
evidence supporting the concept.
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TO THE EDITOR
We appreciate the comments by Dr
Grattan and Dr Brozova to our article
(Eckman et al., 2008) concerning blood
basophil phenotypes and their relation-
ship to autoantibodies in patients with
chronic idiopathic urticaria (CIU).
However, we would like to respond to
their comments.
Grattan stated, ‘‘Unfortunately the
histamine releasing activity of sera was
not assessed by Eckman et aly’’ We
have three main concerns with hista-
mine-releasing activity (HRA). First, the
reliance on a normal basophil donor is
a major concern given the literature’s
demonstration of significant differences
in HRA results depending on who is
chosen as the basophil donor (Grattan
et al., 1991; Kikuchi and Kaplan, 2001).
Second, the reagents and methods are
not standardized, and they differ with
regard to the basophil isolation method,
the ratio of CIU sera to donor basophils,
the use of IL-3 as a basophil enhancer,
and the interpretation and variability
(poor replication) of a positive results
(Vonakis and Saini, 2005). Furthermore,
verification of HRA’s specificity for
autoantibodies by preincubating a CIU
patients sera with soluble FceRIa and
observing a reduction in HRA are
sparse and shown for only selected
datasets. HRA’s specificity is shown by
preincubating the IgG fraction of CIU
patients sera with soluble FceRIa and
then showing a subsequent reduction in
HRA in comparison to a sham control.
Hide et al. only show this inhibition in
4/17 patients, Kikuchi and Kaplan only
show inhibition in 7/111 patients, and
Fiebiger et al. in 9/50 patients (com-
plete sera; IgG fraction not isolated;
Hide et al., 1993; Fiebiger et al., 1998;
Kikuchi and Kaplan, 2001). The inhibi-
tion profiles in these studies are
significantly different. In addition,
Fiebiger showed 9 HRA-negative/
Abbreviation: CIU, chronic idiopathic urticaria; CIU R, CIU responder; CIU NR, CIU non-responder;
HRA, histamine releasing activity
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